1  A series of documents entitled Points to Consider are available from the Director, FDA Center for Biologics Evaluation and Research, HFB-1, 8800 Rockville Pike, Bethesda, MD 20892.

2  This guideline was originally published in the Federal Register, Guidelines for Research Involving Recombinant DNA Molecules 1986; 51 (88): 16957-16985. Copies may be obtained from the Office of Recombinant DNA Activities, 12441 Parklawn Drive, Suite 58, Rockville, MD 20852.

3  A comprehensive guideline, Biosafety in Microbiological and Biomedical Laboratories, is available from the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402, stock #107-040-000508-3.